VTCN1 and neoplasm: As depicted in Figure 5D, the high-response group exhibited elevated expressions of BTLA, LGALS9, PDCD1LG2, TIGIT, TNFSF15, and VTCN1 compared to the low-response group, suggesting that patients with this tumor profile may benefit from ICIs therapy.